Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
BLA FilingapprovedDEGEVMAXgevaPositive
AI Analysis
Summary
Teva Pharmaceutical received FDA approval for DEGEVMA (denosumab-adet), a biosimilar to Xgeva, for preventing bone complications in advanced cancer patients, treating giant cell tumor of bone, and treating hypercalcemia of malignancy. This represents a significant regulatory milestone in Teva's biosimilar portfolio expansion.
Outcome Details
FDA approved DEGEVMA (denosumab-adet) as a biosimilar to Xgeva (denosumab)
Importance:8/10
Sentiment:
0.90
biosimilarFDA approvaldenosumaboncologybone health
Related Companies
Read the original article
Published by GlobeNewswire Pharma on September 28, 2026 8:00 PM